| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
The primary target of antiviral agent 38 is likely a viral protein or host factor essential for viral replication. As an antiviral agent, the compound probably inhibits a specific step in the viral life cycle, such as viral entry, replication, transcription, or assembly. The precise molecular target and mechanism of action require further elucidation through biochemical and virological studies. Target identification is an important step in the development of antiviral agents.
|
|---|---|
| ln Vitro |
In vitro antiviral activity of antiviral agent 38 has been demonstrated in cell culture systems. The compound inhibits viral replication in infected cells, with efficacy measured by reduction in viral titers, viral protein expression, or viral RNA levels. Specific IC₅₀ values and the spectrum of antiviral activity have been reported in the literature. The compound's activity against different virus strains and its selectivity index (SI) are important parameters for evaluation.
|
| ln Vivo |
In vivo efficacy of antiviral agent 38 has been evaluated in appropriate animal models of viral infection. The specific animal model depends on the virus target. The compound's ability to reduce viral load, improve clinical signs, and increase survival has been assessed. Specific in vivo data have been reported in the literature. Further studies are needed to confirm the compound's therapeutic potential and to optimize dosing regimens.
|
| Enzyme Assay |
For antiviral activity screening, standard assays such as plaque reduction assays, cytopathic effect reduction assays, or viral RNA quantification assays are used. Susceptible cell lines are infected with the target virus and treated with serial dilutions of antiviral agent 38. Viral replication is quantified, and EC₅₀ values are calculated. Cytotoxicity is assessed in parallel using standard cell viability assays. Time-of-addition studies may be performed to determine the stage of the viral life cycle affected.
|
| Cell Assay |
For in vitro cell-based studies, susceptible cell lines are cultured in appropriate media and infected with the target virus at an appropriate MOI. Cells are treated with serial dilutions of antiviral agent 38 at various time points relative to infection. Antiviral activity is assessed by measuring viral RNA by RT-qPCR, viral protein expression by Western blotting or immunofluorescence, or infectious virus production by plaque or TCID₅₀ assay. Cell viability is assessed in parallel.
|
| Animal Protocol |
In vivo animal studies for antiviral agents typically use mouse, guinea pig, or ferret models depending on the virus. Animals are infected with the target virus and treated with the test compound via oral, intraperitoneal, or intravenous routes. Efficacy endpoints include survival, weight loss, clinical score, and viral load in tissues. Pharmacokinetic sampling may be included to correlate exposure with efficacy. Standard protocols for antiviral efficacy studies are described in the literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of antiviral agent 38 have been characterized as part of preclinical development. As a small molecule, it is expected to have properties suitable for the intended route of administration. Specific PK parameters such as half-life, clearance, volume of distribution, oral bioavailability, and protein binding have been reported. The compound's metabolism and elimination pathways have also been studied. PK/PD relationships may be evaluated to guide dosing.
|
| Toxicity/Toxicokinetics |
Toxicological data for antiviral agent 38 have been generated as part of preclinical safety assessment. Standard toxicology studies including acute toxicity, repeated-dose toxicity, genotoxicity, and safety pharmacology have been conducted. The compound's safety profile in animal models has been evaluated. Specific toxicity data such as NOAEL and target organ toxicity have been reported. Comprehensive toxicological evaluation is essential for clinical development.
|
| References | |
| Additional Infomation |
Antiviral agent 38 is a research compound for antiviral drug discovery. No clinical trials have been reported for this specific compound. It represents a potential lead compound for the development of antiviral therapeutics. The compound may be used in research studies to validate viral targets or to optimize antiviral activity through medicinal chemistry. Further development would require extensive preclinical and clinical evaluation.
|
| Molecular Formula |
C23H27N3O5
|
|---|---|
| Exact Mass |
425.195
|
| CAS # |
2247932-38-1
|
| PubChem CID |
135365650
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.6
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
31
|
| Complexity |
787
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O(CCCOC)C1=CC=CC2C1=NN1C=2C2=CC(C(C(=O)O)=CN2[C@@H](C1)C(C)(C)C)=O
|
| InChi Key |
RAHUCUNWBZUOGQ-IBGZPJMESA-N
|
| InChi Code |
InChI=1S/C23H27N3O5/c1-23(2,3)19-13-26-21(16-11-17(27)15(22(28)29)12-25(16)19)14-7-5-8-18(20(14)24-26)31-10-6-9-30-4/h5,7-8,11-12,19H,6,9-10,13H2,1-4H3,(H,28,29)/t19-/m0/s1
|
| Chemical Name |
(8R)-8-tert-butyl-13-(3-methoxypropoxy)-4-oxo-7,10,11-triazatetracyclo[8.7.0.02,7.012,17]heptadeca-1(17),2,5,11,13,15-hexaene-5-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
